Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients

Anaesthesia and Intensive Care

Volumn 30, Issue 3, 2002, Pages 269-274

  Dahaba, A A ^a   Elawady, G A ^a   Rehak, P H ^a   List, W F ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Continuous venovenous haemofiltration; CYTOKINES: interleukin 6; Interleukin 1 ; SEPSIS: procalcitonin; Tumour necrosis factor

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CALCITONIN; INTERLEUKIN 1; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMOFILTRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEMOFILTRATION; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; MALE; MEDIATOR; MEMBRANE FILTER; MULTIPLE ORGAN FAILURE; PLASMA CLEARANCE; PROGNOSIS; SEPSIS; ULTRAFILTRATION; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; METABOLISM; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PROBABILITY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CALCITONIN; CYTOKINES; FEMALE; HEMOFILTRATION; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; SEPSIS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035986102     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0203000302     Document Type: Article

References (19)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
2. The pathogenesis of sepsis
3. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis
4. High serum procalcitonin concentrations in patients with sepsis and infection
5. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind placebo-controlled trial
6. Influence of an anti-tumour necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
7. Prognosis in acute organ system failure
8. Cytokine removal during continuous hemofiltration in septic patients
9. Plasma concentrations and clearance of procalcitonin during continuous veno-venous hemofiltration in septic patients
10. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNFα plasma concentrations
11. Diffusive vs. convective therapy: Effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome
12. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration
13. Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances
14. Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis
15. Proinflammatory cytokines and hemofiltration membranes
16. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function
17. Removal of pro-inflammatory cytokines with renal replacement therapy: Sense or non-sense?
18. Comparison of procalcitonin, sCD14 and interleukin-6 values in septic patients
19. 1-antitrypsin, and lactoferrin compared with clinical variables